Abstract 1684P
Background
Survival rates for cancer have improved steadily. Consequently, the late physical and psychological effects of treatment may negatively impact the well-being of cancer survivors. This study aimed to provide an overview of patients' lives after remission and their evolving perceptions.
Methods
In the absence of a validated questionnaire suitable to our study, we conducted a cross-sectional survey including 110 cancer survivors regardless of gender, age, and cancer site using a self-developed questionnaire designed to explore various aspects of survivors’ lives, including functional, social and emotional well-being.
Results
Median age was 58 years [37-81] and 75% of patients were women. Median follow up was 45 months [24-101]. Breast cancer was the most common cancer (44%), followed by colorectal (32.7%) and gynecologic (17.3%) cancers. All patients received chemotherapy, 33% had hormone therapy, 65.5% had radiotherapy and 96 % underwent surgery. Thirty-three patients (30%) reported ongoing fatigue and lack of energy, while 25.9% experienced cognitive decline. Persistent pain was reported by 40% of survivors. Those treated with oxaliplatin or taxane-based chemotherapy reported peripheral neuropathy in 38.4% of cases. Positive lifestyle changes were reported in 42 patients (38.9%), including adoption of healthier eating habits (40.9%), engaging in sports (31%), and an increased commitment to religious practices (14.3%). Sixty-one percent of patients resumed work, with 15.7% undergoing job reassignment. Sixty percent expressed greater appreciation for life post-cancer, and 70.9% felt their lives had acquired deeper meaning. Fear of cancer recurrence (FCR) was reported by 44 patients (40%), significantly more prevalent among females (61% vs 40%, p=0.038) and those under 50 years old (69% vs 42%, p=0.001). Sleep disturbances were reported by 41 patients (37.3%), significantly impacted by FCR (OR= 3.77 [1.12-7.87]) and pain (OR= 2.56 [1.08-5.87]).
Conclusions
Years after cancer, patients have to deal with changes concerning their physical and emotional well-being. Thus, treatment protocols should be well-considered and follow-up programs should target these disturbances timely.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1627P - Long survivors after androgen deprivation therapy (ADT) with or without docetaxel for metastatic castration-sensitive prostate cancer (mCSPC): Long-term follow-up of GETUG-15
Presenter: Sarah Blanchet-Deverly
Session: Poster session 11
1628P - Factors influencing clinical and biological response in patients treated with [177Lu]Lu-PSMA-617 under France's early access program
Presenter: Vincent Habouzit
Session: Poster session 11
1629P - Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) therapy in patients (pts) with prior Radium-223 (223Ra)
Presenter: Kambiz Rahbar
Session: Poster session 11
1630P - A multicenter retrospective study on the efficacy of anti-PD-(L)1 in microsatellite unstable (MSI-H) metastatic castrate-resistant prostate cancer (mCRPC)
Presenter: Sandra Van Wilpe
Session: Poster session 11
1632P - Impact of androgen pathway inhibitors on cognitive function in elderly patients with metastatic prostate cancer: Results from the COG-PRO trial
Presenter: Antoine Boué
Session: Poster session 11
1634P - Does lower serum testosterone predict metastases-free survival in nmCRPC patients treated with novel antiandrogens? A post-hoc analysis of SPARTAN and ARAMIS
Presenter: Xudong Ni
Session: Poster session 11
1635P - Validation of automated bone scan index as a progression endpoint in two phase III studies of metastatic castration resistant prostate cancer (mCRPC) patients
Presenter: Andrea Knezevic
Session: Poster session 11